Home › Regulatory Perspective Therapeutics, Inc. - 8-K Filing Perspective Therapeutics receives FDA Fast Track Designation for PSV359 in treating FAP-positive solitary fibrous tumors. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
7 articles from 1 source · updated October 14, 2026, 14:04 UTC
Coverage SAB Biotherapeutics, Inc. - 8-K Filing SEC EDGAR · October 13, 2026, 12:37 UTC ADC Therapeutics SA - 8-K Filing SEC EDGAR · October 13, 2026, 10:27 UTC Nurix Therapeutics, Inc. - 10-Q Filing SEC EDGAR · October 13, 2026, 10:22 UTC Nurix Therapeutics, Inc. - 8-K Filing SEC EDGAR · October 13, 2026, 10:20 UTC Rapport Therapeutics, Inc. - 4 Filing SEC EDGAR · October 8, 2026, 20:07 UTC Vir Biotechnology, Inc. - 8-K Filing SEC EDGAR · October 8, 2026, 12:40 UTC Perspective Therapeutics, Inc. - 8-K Filing SEC EDGAR · October 8, 2026, 10:29 UTC